|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||12.15 - 12.15|
|52-week range||4.75 - 14.00|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
7 November 2019 LIMITLESS EARTH PLC ("Limitless" or the "Company") Change of Registered Office Limitless Earth plc, an AIM quoted investing company, announces that it has changed its ...
24 September 2019 LIMITLESS EARTH PLC ("Limitless" or the "Company") Result of AGM At the Company’s Annual General Meeting held earlier today, all resolutions were duly passed. For ...
Limitless Earth plc (“Limitless”), an AIM quoted investing company, is pleased to announce that it has made a further investment in Chronix Biomedical, Inc. (“Chronix”), a developer of novel blood-based cancer molecular diagnostics, of approximately US$100,000. Limitless previously announced an investment in Chronix on 8 October 2015 of US$500,000 (approximately £329,511) by way of convertible preference stock at a price of US$0.40 per share at a valuation of approximately US$69 million.
31 July 2019 LIMITLESS EARTH PLC ("Limitless" or the "Company") Final Results for the year to 31 January 2019 and Notice of AGM The Company announces its final results for the year ...